Avalo Therapeutics, Inc.
AVTX
$18.20
$0.201.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -49.29% | 61.18% | -232.94% | -121.09% | 89.16% |
| Total Depreciation and Amortization | -87.41% | -76.47% | 73.53% | 306.06% | 297.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.16% | -103.45% | 146.38% | 104.96% | -97.97% |
| Change in Net Operating Assets | -190.14% | 128.76% | 23.95% | 372.55% | 194.77% |
| Cash from Operations | -87.07% | 5.30% | -41.97% | 30.05% | -52.48% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -98.35% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 73.36% | -- | -- | -- |
| Cash from Financing | -- | -98.99% | -- | 0.64% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 197.42% | -121.19% | -32.36% | -393.70% | -109.20% |